Abstract: A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditions is described. The combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin is also useful for cosmetic treatment of skin and as an antibacterial agent.

Abstract: The invention relates to a new use of NAC in IVF, in a human or mammalian animal patient. In addition an effective dose regimen of NAC in IVF is proposed.

Abstract: An apparatus for analyzing a sample, including a sample receiving device, a gas chromatograph and a spectrophotometer, said spectrophotometer including a UV Light Emitting Diode as the light source, an elongated chamber and a detector. The UV light source is arranged to illuminate sample substances conducted through the chamber, and the detector is arranged to identify sample substances by UV absorption spectroscopy.

Abstract: The invention relates to a new use of NAC in IVF, in a human or mammalian animal patient. In addition an effective dose regimen of NAC in IVF is proposed.

Abstract: The present invention relates to the use of substances with oxytocin activity against climacteric disorders or similar symptoms due to dysfunction in the ovaries. It also relates to a pharmaceutical composition comprising at least one substance with oxytocin activity against climacteric disorders.

Abstract: The present invention relates to the use di-, tri- and tetrapeptide fragments of oxytocin or mesotocin for the preparation of a pharmaceutical composition in order to create eustasis. The invention also relates to di-, tri- and tetrapeptide fragments of oxytocin or mesotocin for medical use, as well as a pharmaceutical composition comprising at least one di-, tri- or tetrapeptide fragment of oxytocin or mesotocin in order to create eustasis.

Abstract: A method of treating cancer in situ and cervicitis is disclosed. A pharmaceutical composition comprising at least one substance with oxytocin activity against cancer in situ and cervicitis and compound of the formula SEQ ID NO:2 is also disclosed.

Abstract: The present invention relates to the use of substances with oxytocin for the preparation of pharmaceutical composition against inflamation. It also relates to a pharmaceutical composition comprising at least one substance with oxytocin activity against inflamation.

Abstract: The present invention relates to the use of substances with oxytocin activity against climacteric disorders or similar symptoms due to dysfunction in the ovaries. It also relates to a pharmaceutical composition comprising at least one substance with oxytocin activity against climacteric disorders.

Abstract: The present invention relates to the use di-, tri- and tetrapeptide fragments of oxytocin or mesotocin for the preparation of a pharmaceutical composition in order to create eustasis. The invention also relates to di-, tri- and tetrapeptide fragments of oxytocin or mesotocin for medical use, as well as a pharmaceutical composition comprising at least one di-, tri- or tetrapeptide fragment of oxytocin or mesotocin in order to create eustasis.

Abstract: The present invention relates to the use of substances with oxytocin activity for the preparation of a pharmaceutical composition against cancer in situ and cervicitis. It also relates to a pharmaceutical composition comprising at least one substance with oxytocin activity against cancer in situ and cervicitis. It also relates to a compound of the formula SEQ ID NO:2.

Abstract: The invention relates to the use of an effective dose of N-acetyl-L-cysteine, or a dimeric form thereof, for the manufacturing of a drug for reverting mammalian neoplasia cells of epithelial origin back to a normal differentiation whereby the abnormal proliferation of the neoplasia cells is reverted to a normal pathway.

Abstract: The present invention relates to the use of substances with oxytocin activity against climacteric disorders or similar symptoms due to dysfunction in the ovaries. It also relates to a pharmacetucial composition comprising at least one substance with oxytocin activity against climacteric disorders.

Abstract: Substances having oxytocin activity can be used for the preparation of a pharmaceutical composition for the curative or prophylactic treatment of wounds, such as chronic wounds. The wound healing effect can be strengthened or prolonged by combining oxytocin with estrogen.

Abstract: Metallic silver is deposited upon the surface of a nonconducting substrate using a multi-step wet deposition process. The surface is cleaned, and then activated in an aqueous solution containing stannous tin. The silver is deposited as a colloidal material from an aqueous solution of a silver-containing salt, a reduction agent that reduces the salt to form the metallic silver, and a deposition control agent that prevents the silver from nucleating throughout the solution. After the substrate is coated, the coating is stabilized in an aqueous solution of a salt of a metal from the platinum group or gold, dissolved in dilute hydrochloric acid. The process is particularly effective for depositing uniform-films of 2 to 2000 Angstroms thickness, which strongly adhere to the substrate.

Abstract: Metallic silver is deposited upon the surface of a nonconducting substrate using a multi-step wet deposition process. The surface is cleaned, and then activated in an aqueous solution containing stannous tin. The silver is deposited as a colloidal material from an aqueous solution of a silver-containing salt, a reduction agent that reduces the salt to form the metallic silver, and a deposition control agent that prevents the silver from nucleating throughout the solution. After the substrate is coated, the coating is stabilized in an aqueous solution of a salt of a metal from the platinum group or gold, dissolved in dilute hydrochloric acid. The process is particularly effective for depositing uniform films of 2 to 2000 Angstroms thickness, which strongly adhere to the substrate.

Abstract: A thin silver layer is deposited on the surface of a nonconducting substrate using an electroless process. The surface is cleaned and activated in aqueous solution containing stannous tin. The silver is deposited as a colloidal material from an aqueous solution of a silver-containing salt in the absence of an electric current, but in the presence of a deposition control agent. Optionally, the silver layer is stabilized with an aqueous solution of a platinum-group metal and/or gold. The resulting silver layer is uniform and of 2-2000 .ANG. thickness; it strongly adheres to the substrate.

Abstract: Metallic silver is deposited upon the surface of a nonconducting substrate using a multi-step wet deposition process. The surface is cleaned, and then activated in an aqueous solution containing stannous tin. The silver is deposited as a colloidal material from an aqueous solution of a silver-containing salt, a reduction agent that reduces the salt to form the metallic silver, and a deposition control agent that prevents the silver from nucleating throughout the solution. After the substrate is coated, the coating is stabilized in an aqueous solution of a salt of a metal from the platinum group or gold, dissolved in dilute hydrochloric acid. The process is particularly effective for depositing uniform films of 2 to 2000 Angstroms thickness, which strongly adhere to the substrate.

Abstract: Metallic silver is deposited upon the surface of a nonconducting substrate using a multi-step wet deposition process. The surface is cleaned, and then activated in an aqueous solution containing stannous tin. The silver is deposited as a colloidal material from an aqueous solution of a silver-containing salt, a reduction agent that reduces the salt to form the metallic silver, and a deposition control agent that prevents the silver from nucleating throughout the solution. After the substrate is coated, the coating is stabilized in an aqueous solution of a salt of a metal from the platinum group of gold, dissolved in dilute hydrochloric acid. The process is particularly effective for depositing uniform films of 2 to 2000 Angstroms thickness, which strongly adhere to the substrate.